These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 29202216)

  • 1. Type II-C CRISPR-Cas9 Biology, Mechanism, and Application.
    Mir A; Edraki A; Lee J; Sontheimer EJ
    ACS Chem Biol; 2018 Feb; 13(2):357-365. PubMed ID: 29202216
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diverse Class 2 CRISPR-Cas Effector Proteins for Genome Engineering Applications.
    Pyzocha NK; Chen S
    ACS Chem Biol; 2018 Feb; 13(2):347-356. PubMed ID: 29121460
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition Mechanism of an Anti-CRISPR Suppressor AcrIIA4 Targeting SpyCas9.
    Yang H; Patel DJ
    Mol Cell; 2017 Jul; 67(1):117-127.e5. PubMed ID: 28602637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Revolution Continues: Newly Discovered Systems Expand the CRISPR-Cas Toolkit.
    Murugan K; Babu K; Sundaresan R; Rajan R; Sashital DG
    Mol Cell; 2017 Oct; 68(1):15-25. PubMed ID: 28985502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fanzor is a eukaryotic programmable RNA-guided endonuclease.
    Saito M; Xu P; Faure G; Maguire S; Kannan S; Altae-Tran H; Vo S; Desimone A; Macrae RK; Zhang F
    Nature; 2023 Aug; 620(7974):660-668. PubMed ID: 37380027
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A G-quadruplex motif at the 3' end of sgRNAs improves CRISPR-Cas9 based genome editing efficiency.
    Nahar S; Sehgal P; Azhar M; Rai M; Singh A; Sivasubbu S; Chakraborty D; Maiti S
    Chem Commun (Camb); 2018 Mar; 54(19):2377-2380. PubMed ID: 29450416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cas13d Is a Compact RNA-Targeting Type VI CRISPR Effector Positively Modulated by a WYL-Domain-Containing Accessory Protein.
    Yan WX; Chong S; Zhang H; Makarova KS; Koonin EV; Cheng DR; Scott DA
    Mol Cell; 2018 Apr; 70(2):327-339.e5. PubMed ID: 29551514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Crystal Structure of the Minimal Cas9 from Campylobacter jejuni Reveals the Molecular Diversity in the CRISPR-Cas9 Systems.
    Yamada M; Watanabe Y; Gootenberg JS; Hirano H; Ran FA; Nakane T; Ishitani R; Zhang F; Nishimasu H; Nureki O
    Mol Cell; 2017 Mar; 65(6):1109-1121.e3. PubMed ID: 28306506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identifying Novel Enhancer Elements with CRISPR-Based Screens.
    Klein JC; Chen W; Gasperini M; Shendure J
    ACS Chem Biol; 2018 Feb; 13(2):326-332. PubMed ID: 29300083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization and Repurposing of Type I and Type II CRISPR-Cas Systems in Bacteria.
    Hidalgo-Cantabrana C; Goh YJ; Barrangou R
    J Mol Biol; 2019 Jan; 431(1):21-33. PubMed ID: 30261168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CRISPR-Cas12 and Cas13: the lesser known siblings of CRISPR-Cas9.
    Yan F; Wang W; Zhang J
    Cell Biol Toxicol; 2019 Dec; 35(6):489-492. PubMed ID: 31468291
    [No Abstract]   [Full Text] [Related]  

  • 12. Identification of RNA Binding Partners of CRISPR-Cas Proteins in Prokaryotes Using RIP-Seq.
    Sharma S; Sharma CM
    Methods Mol Biol; 2022; 2404():111-133. PubMed ID: 34694606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Methods for Optimizing CRISPR-Cas9 Genome Editing Specificity.
    Tycko J; Myer VE; Hsu PD
    Mol Cell; 2016 Aug; 63(3):355-70. PubMed ID: 27494557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Editor's cut: DNA cleavage by CRISPR RNA-guided nucleases Cas9 and Cas12a.
    Swartjes T; Staals RHJ; van der Oost J
    Biochem Soc Trans; 2020 Feb; 48(1):207-219. PubMed ID: 31872209
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Type III CRISPR-Cas System: Introduction And Its Application for Genetic Manipulations.
    Liu T; Pan S; Li Y; Peng N; She Q
    Curr Issues Mol Biol; 2018; 26():1-14. PubMed ID: 28879852
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Probing the structural dynamics of the CRISPR-Cas9 RNA-guided DNA-cleavage system by coarse-grained modeling.
    Zheng W
    Proteins; 2017 Feb; 85(2):342-353. PubMed ID: 27936513
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural Variation of Type I-F CRISPR RNA Guided DNA Surveillance.
    Pausch P; Müller-Esparza H; Gleditzsch D; Altegoer F; Randau L; Bange G
    Mol Cell; 2017 Aug; 67(4):622-632.e4. PubMed ID: 28781236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design and Evaluation of Guide RNA Transcripts with a 3'-Terminal HDV Ribozyme to Enhance CRISPR-Based Gene Inactivation.
    Berkhout B; Gao Z; Herrera-Carrillo E
    Methods Mol Biol; 2021; 2167():205-224. PubMed ID: 32712922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction and Validation of Native and Engineered Cas9 Guide Sequences.
    Briner AE; Henriksen ED; Barrangou R
    Cold Spring Harb Protoc; 2016 Jul; 2016(7):. PubMed ID: 27371591
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Programming PAM antennae for efficient CRISPR-Cas9 DNA editing.
    Wang F; Hao Y; Li Q; Li J; Zhang H; Zhang X; Wang L; Bustamante C; Fan C
    Sci Adv; 2020 May; 6(19):eaay9948. PubMed ID: 32494703
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.